Stock ACIU AC IMMUNE SA
Add to a list
To use this feature you must be a member
Log inSign up

News AC Immune SA

Equities

ACIU

CH0329023102

Delayed Nasdaq
Other stock markets
 13:02:40 2024-04-29 EDT 		5-day change 1st Jan Change
2.44 USD +3.83% Intraday chart for AC Immune SA +0.83% -51.20%
03-15 AC Immune Files $350 Million Mixed Shelf MT
03-14 AC Immune SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AC Immune Files $350 Million Mixed Shelf
MT
AC Immune SA Reports Earnings Results for the Full Year Ended December 31, 2023
CI
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
AQ
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
AQ
Certain Common Shares of AC Immune SA are subject to a Lock-Up Agreement Ending on 14-FEB-2024.
CI
AC Immune to Regain Global Rights of Crenezumab, Semorinema
MT
Roche terminates licensing agreement with AC Immune
CF
AC Immune SA Announces Termination of the Research Collaboration and License Agreement with Genentech, Inc
CI
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
AQ
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson's Diseases
CI
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
AQ
AC Immune : Underwriting Agreement - Form 6-K
PU
AC Immune's Targeted Anti-PTau Active Immunotherapy for Alzheimer's disease Advances into Phase 2b Trial
AQ
AC Immune Announces Pricing of Underwritten Offering of Common Shares
AQ
AC Immune SA(NasdaqGM:ACIU) added to NASDAQ Biotechnology Index
CI
Sector Update: Health Care Stocks Retreating Late Afternoon
MT
Sector Update: Health Care Stocks Softer in Afternoon Trading
MT
AC Immune Announces Pricing of Underwritten Offering of Common Shares
AQ
AC Immune SA Announces its Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial
CI
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ACIU Stock
  4. News AC Immune SA